Haemonetics (HAE) analyst forecast and price target
Analyst forecast
Consensus of 12 analyst ratings
Based on 6 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Baird | Maintained | Outperform | $119.00 from $96.00 | Aug 21, 2026 |
| Barrington Research | Maintained | Outperform | $118.00 from $95.00 | Aug 19, 2026 |
| BTIG | Maintained | Buy | $110.00 from $96.00 | Aug 18, 2026 |
| JP Morgan | Maintained | Neutral | $86.00 from $62.00 | Aug 7, 2026 |
| Citigroup | Maintained | Neutral | $92.00 from $79.00 | Aug 7, 2026 |
| BTIG | Maintained | Buy | $96.00 from $84.00 | Aug 6, 2026 |
| Mizuho | Maintained | Outperform | $90.00 from $85.00 | Jul 15, 2026 |
| BTIG | Maintained | Buy | $84.00 | Jun 26, 2026 |
| BTIG | Maintained | Buy | $84.00 | Jun 17, 2026 |
| Mizuho | Maintained | Outperform | $85.00 from $70.00 | Jun 15, 2026 |
| Citigroup | Maintained | Neutral | $70.00 from $64.00 | May 28, 2026 |
| B of A Securities | Upgraded | Neutral → Buy | $80.00 from $72.00 | May 22, 2026 |
| Barrington Research | Maintained | Outperform | $89.00 from $94.00 | May 12, 2026 |
| JP Morgan | Maintained | Neutral | $62.00 from $74.00 | May 8, 2026 |
| Mizuho | Maintained | Outperform | $70.00 from $80.00 | Apr 13, 2026 |
| Citigroup | Maintained | Neutral | $70.00 from $75.00 | Mar 11, 2026 |
| Barrington Research | Maintained | Outperform | $94.00 from $93.00 | Feb 6, 2026 |
| Mizuho | Maintained | Outperform | $80.00 from $90.00 | Feb 6, 2026 |
| BTIG | Maintained | Buy | $88.00 | Feb 6, 2026 |
| Citigroup | Maintained | Neutral | $75.00 from $88.00 | Feb 6, 2026 |
Frequently asked questions
What is the price target for HAE stock?
The average 12-month analyst price target for Haemonetics (HAE) is $102.50, with a high estimate of $119.00 and a low of $86.00, across 6 analysts.
Is HAE a buy, sell, or hold?
Analysts covering Haemonetics currently average a Buy rating: 8 buy, 4 hold and 0 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for HAE?
The average price target of $102.50 implies 0.06% upside from the last price of $102.44.
What is the latest analyst rating on HAE?
On Aug 21, 2026, Baird maintained Haemonetics at Outperform with a price target of $119.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.